Publications by authors named "Jeannine Huisbrink"

Article Synopsis
  • Sodium-glucose cotransporter 2 inhibitors (SGLT2i), like dapagliflozin, may help improve cardiovascular outcomes in type 2 diabetes but their exact protective mechanisms are not fully understood.
  • * In a study involving 14 male patients with type 2 diabetes, dapagliflozin led to a significant reduction in the daily insulin dose but did not change fasting or postprandial glucose or insulin levels.
  • * Results indicated that dapagliflozin increased postprandial ketone bodies and decreased fasting chylomicron remnants, suggesting it may enhance fat oxidation without affecting lipid levels or inflammatory markers.*
View Article and Find Full Text PDF

Introduction: Fast-track protocols often include short-term thromboprophylaxis and short length of hospital stay. These treatment strategies may negatively affect the occurrence and diagnosis of postoperative haemorrhage. Over the years, the rates of venous thromboembolic events (VTEs) have decreased, while there seems to be an increase in the occurrence of postoperative haemorrhage.

View Article and Find Full Text PDF

Aim: Type 2 diabetes mellitus (T2DM) is associated with an increased risk of cardiovascular disease (CVD) linked to atherogenic dyslipidaemia and postprandial hyperlipidaemia. Alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, improves CVD risk by reducing the concentration of low-density lipoprotein-cholesterol (LDL-C). However, effects of PCK9 inhibitors on other aspects of diabetic dyslipidaemia, particularly in the postprandial situation, are less clear.

View Article and Find Full Text PDF

Optimal survival benefit from different lines of anticancer treatment in advanced nonsmall cell lung cancer (NSCLC) requires conservation of renal function. We evaluated the development of renal impairment during pemetrexed maintenance.In a prospective multicentre cohort study, we evaluated the incidence of acute/chronic kidney disease (AKD/CKD), its related treatment discontinuation frequency and associated clinical variables with AKD in patients with stage IIIB/IV NSCLC treated with pemetrexed maintenance.

View Article and Find Full Text PDF

We conducted a cohort-study among 518 female 5-year Hodgkin lymphoma (HL) survivors, aged 14 to 40 years (median: 25 years) at treatment (1965-1995). Multivariable Cox regression was used to quantify treatment effects on risk of premature menopause, defined as cessation of menses before age 40 years. After a median follow up of 9.

View Article and Find Full Text PDF